 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. Nasdaq:IMV; TSX:IMV IMV or the Company, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that durable clinical benefits induced by combination treatment of IMVs T cell therapy with Mercks Keytruda pembrolizumab in subjects with PD-L1 positive recurrentrefractory Diffuse Large B Cell Lymphoma rr DLBCL have been presented at the 